Xbrane And Biogen Ally On Certolizumab Pegol Biosimilar

Xbrane CEO Martin Åmark Highlights Potential For Xcimzane Rival To Cimzia

 
• By Dave Wallace

Xbrane Biopharma and Biogen have struck a licensing deal for Xbrane’s Xcimzane certolizumab pegol proposed biosimilar rival to Cimzia. In the wake of the announcement, Xbrane CEO Martin Åmark offered details on the partnership as well as the product’s commercial potential.

Certolizumab Pegol green background
Xbrane has secured Biogen as a partner on its Xcimzane certolizumab pegol biosimilar • Source: molekuul.be / Alamy Stock Photo

More from Deals

More from Business